A detailed history of Citigroup Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Citigroup Inc holds 143,441 shares of BPMC stock, worth $13 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
143,441
Previous 120,252 19.28%
Holding current value
$13 Million
Previous $13 Million 2.33%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$84.1 - $120.5 $1.95 Million - $2.79 Million
23,189 Added 19.28%
143,441 $13.3 Million
Q2 2024

Aug 12, 2024

BUY
$85.18 - $108.78 $1.4 Million - $1.78 Million
16,389 Added 15.78%
120,252 $13 Million
Q1 2024

May 10, 2024

SELL
$73.17 - $99.79 $5.47 Million - $7.46 Million
-74,794 Reduced 41.86%
103,863 $9.85 Million
Q4 2023

Feb 09, 2024

BUY
$43.96 - $92.84 $4.71 Million - $9.95 Million
107,205 Added 150.04%
178,657 $16.5 Million
Q3 2023

Nov 09, 2023

BUY
$46.9 - $66.0 $515,196 - $725,010
10,985 Added 18.17%
71,452 $3.59 Million
Q2 2023

Aug 10, 2023

SELL
$42.2 - $66.37 $3.71 Million - $5.83 Million
-87,840 Reduced 59.23%
60,467 $3.82 Million
Q1 2023

May 11, 2023

BUY
$37.97 - $50.0 $2.32 Million - $3.05 Million
60,988 Added 69.85%
148,307 $6.67 Million
Q4 2022

Feb 09, 2023

SELL
$41.06 - $66.48 $544,332 - $881,325
-13,257 Reduced 13.18%
87,319 $3.83 Million
Q3 2022

Nov 10, 2022

BUY
$49.93 - $77.7 $632,712 - $984,614
12,672 Added 14.42%
100,576 $6.63 Million
Q2 2022

Aug 10, 2022

BUY
$45.23 - $70.15 $2.94 Million - $4.55 Million
64,922 Added 282.49%
87,904 $4.44 Million
Q1 2022

May 12, 2022

SELL
$54.1 - $110.08 $2.17 Million - $4.42 Million
-40,179 Reduced 63.61%
22,982 $1.47 Million
Q4 2021

Feb 10, 2022

BUY
$94.25 - $115.99 $382,278 - $470,455
4,056 Added 6.86%
63,161 $6.77 Million
Q3 2021

Nov 10, 2021

BUY
$80.98 - $109.47 $4.79 Million - $6.47 Million
59,105 New
59,105 $6.08 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.